BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

Celaid and AGC Partner in Japan to Advance Scalable Expansion of iPSC-Derived Blood Stem Cells

Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem a...

August 29, 2025 | News

Hope Biosciences Receives First RMAT Designation For Stem Cell Therapy In Multiple Sclerosis

Leading U.S. stem cell banking and cellular therapeutic manufacturer Hope Biosciences announces the U.S. Food and Drug Administration (FDA) has g...

August 28, 2025 | News

Northwest Biotherapeutics To Acquire Advent BioServices, Bringing Manufacturing Operations In-House

Northwest Biotherapeutics, Inc. , a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it ha...

August 28, 2025 | News

Cartherics Secures Chinese Patent for Gene-Edited Immune Cell Therapy Targeting Solid Tumours

Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies f...

August 27, 2025 | News

Abbott Secures Thailand Approval For Denosumab Biosimilar Expanding Access To Osteoporosis Treatment

Abbott denosumab biosimilar has received regulatory approval in Thailand, expanding access to advanced therapies for osteoporosis and cancer-related bone l...

August 27, 2025 | News

iNtRON Bio Files Patents for Groundbreaking IMPA™ Gene-Editing Technology Targeting Pasteurella Bacteriophages

Development of gene-editing technology for Pasteurella bacteriophages using the IMPA™ platform Establishment of an advanced platform tec...

August 27, 2025 | News

Leads Biolabs Doses First Patient In Phase II Trial Of LBL-034, China’s First Potential GPRC5D-Targeted T-Cell Engager

Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...

August 26, 2025 | News

AbbVie To Acquire Gilgamesh’s Lead Psychedelic Compound Bretisilocin For Up To $1.2 Billion

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of m...

August 26, 2025 | News

Asia Bio Innovation Summit 2025 Highlights ADC and CGT as Dual Engines of Biopharma Innovation

Asia Bio Innovation Summit 2025 is one of the premier industry-focused events in Asia and focus on the hottest topics of ADC and CGT. Asia B...

August 25, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

China’s Bio-Thera and Europe’s STADA Expand Biosimilars Alliance to Include Tocilizumab

Bio-Thera and STADA agree to extend their biosimilars alliance to cover tocilizumab, a targeted immunomodulatory monoclonal antibody directed against the...

August 25, 2025 | News

BioDlink Secures Indonesian Approval for Bevacizumab, Accelerating ASEAN and Global Expansion

BioDlink announced that its Bevacizumab Injection has obtained marketing authorization from Indonesia's National Agency of Drug and Food Con...

August 22, 2025 | News

Andelyn Biosciences Partners with Amplo Biotechnology to Advance AAV Gene Therapies for NMJ Disorders

Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered wi...

August 22, 2025 | News

Japan’s ARC Therapies Initiates Research on Novel Gut Microbe YB328 for Cancer Immunotherapy

ARC Therapies Inc. (Head Office: Shinjuku, Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Cente...

August 21, 2025 | News

Stay Connected